Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals

From the Editor

June, 2017

27 June
June 27, 2017

I had the good fortune of attending a Children with Diabetes conference some 10 years ago at Disney World in Orlando. During this conference, many of the kids had been keeping their insulin in their room refrigerators. One morning, some of the kids woke to find their insulin either frozen ...
Read More »

Latest Articles

June, 2017

27 June
Monitoring Insulin Temperature

I have type 1 diabetes and have been living with it for the past 11 years. I take daily insulin injections to stay alive and well. A couple of years ago, I had a very frustrating incident when my insulin stopped working. I began injecting loads of insulin, and even with multiple doses my blood glucose wouldn’t drop.
Read More »
27 June
Israel Hartman Transcript

Dr. Hartman discusses diabetes, hyperlipidemia and obesity, and why it is crucial to treat obesity as a clinical condition, not a willpower issue.
Read More »
27 June
Israel Hartman Full Interview

In this Exclusive Interview, Dr. Hartman discuss practical points in the approach of the patient with diabetes, hyperlipidemia and obesity.
Read More »
27 June
Insulin & Vascular Function Part 10

In this week's Homerun Slides, the initiation of basal insulin.
Read More »
27 June
International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #80: Insulin Actions In Vivo: Glucose Metabolism Part 6 of 9

Intravenous glucose: In the presence of euglycemia, insulin displays a potent suppressive action on hepatic glucose production, such that portal insulin concentrations of less than 100 mU L−1 abolish glucose entry into the circulation. Figure 14.7 shows a typical time course for endogenous glucose production following an acute increase in plasma insulin to levels of 60 – 70 mU L−1 in a healthy subject.
Read More »

Test Your Knowledge

GLP-1 and Basal Insulin

Which of the following GLP-1 agonists is not currently approved for use with basal insulin?

	A. Exenatide (Byetta)
	B. Dulaglutide (Trulicity)
	C. Albiglutide (Tanzeum)
	D. Liraglutide (Victoza)
	E. None of the above

Correct

Explanation: The other three medications (exenatide, albiglutide and liraglutide) have all been approved for concomitant use with basal insulin but have not been studied with prandial insulin. Current studies are ongoing to evaluate the safety and, in particular, the incidence of hypoglycemia when dulaglutide is used together with basal insulin. According to the package insert for all these drugs, when being used with an insulin secretagogue or with insulin itself, the dose should be lowered.

Incorrect